Related Experiment Videos
Clinical trials of beta-blockers in heart failure: a class review
1Division of Cardiology, Congestive Heart Failure Program, The University of Texas Southwestern Medical Center, Dallas, Texas 75235-9047, USA.
Insights
Heart failure management has improved with neurohormonal response agents. Angiotensin-converting enzyme (ACE) inhibitors are standard, and beta blockers show promise in reducing heart failure symptoms and mortality.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure presents a significant clinical challenge with high mortality rates.
- Neurohormonal response modulation has improved outcomes in chronic left-ventricular dysfunction.
Purpose of the Study:
- To review the role of ACE inhibitors and beta blockers in heart failure management.
- To highlight current evidence and ongoing research regarding these therapies.
Main Methods:
- Review of existing clinical data and trial results.
- Analysis of the impact of ACE inhibitors and beta blockers on heart failure progression and survival.
Main Results:
- Angiotensin-converting enzyme (ACE) inhibitors are indicated for all heart failure patients, slowing disease progression and reducing mortality.
- Beta blockers, when added to standard therapy in appropriate patients, alleviate heart failure symptoms, decrease hospitalizations, and improve survival.
Conclusions:
- ACE inhibitors are a cornerstone of heart failure treatment.
- Beta blockers offer significant benefits in heart failure management, though optimal use requires further investigation through ongoing trials.
Abstract:
Heart failure remains a clinically challenging illness, with increasing incidence and prevalence and a high risk of mortality. The introduction of agents that interfere with the neurohormonal response to chronic left-ventricular dysfunction has resulted in improved patient outcomes. Owing to slowed disease progression and reduced mortality, angiotensin-converting enzyme (ACE) inhibitors are indicated in all patients with heart failure. New data indicate that in appropriate patients, beta-blocker therapy relieves the symptoms associated with heart failure, reduces hospitalizations, and improves survival when added to standard therapy. Questions still remain regarding the ideal use of beta blockers in heart failure, and ongoing trials will attempt to clarify those points.